CN103721142A - 一种防治龟头炎的中药洗液及其制备方法 - Google Patents
一种防治龟头炎的中药洗液及其制备方法 Download PDFInfo
- Publication number
- CN103721142A CN103721142A CN201310752658.3A CN201310752658A CN103721142A CN 103721142 A CN103721142 A CN 103721142A CN 201310752658 A CN201310752658 A CN 201310752658A CN 103721142 A CN103721142 A CN 103721142A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- balanitis
- chinese medicinal
- lotion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 77
- 208000002479 balanitis Diseases 0.000 title claims abstract description 69
- 239000006210 lotion Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims description 26
- 239000007788 liquid Substances 0.000 claims description 54
- 229940079593 drug Drugs 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000010438 heat treatment Methods 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 14
- 238000010992 reflux Methods 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- 239000012286 potassium permanganate Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 241000219295 Portulaca Species 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000007873 sieving Methods 0.000 claims description 9
- 230000000249 desinfective effect Effects 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 6
- 241000545442 Radix Species 0.000 claims description 6
- 241001529553 Scoparia <angiosperm> Species 0.000 claims description 6
- 241000207929 Scutellaria Species 0.000 claims description 6
- 229940097275 indigo Drugs 0.000 claims description 6
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 4
- 238000010410 dusting Methods 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 2
- 239000013618 particulate matter Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 206010061218 Inflammation Diseases 0.000 abstract description 12
- 230000004054 inflammatory process Effects 0.000 abstract description 12
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 7
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 4
- 241000244987 Daiswa polyphylla Species 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 244000234609 Portulaca oleracea Species 0.000 abstract 2
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 240000000774 Cunila origanoides Species 0.000 abstract 1
- 235000018274 Cunila origanoides Nutrition 0.000 abstract 1
- 235000014866 Dictamnus albus Nutrition 0.000 abstract 1
- 244000148137 Patrinia villosa Species 0.000 abstract 1
- 235000019109 Patrinia villosa Nutrition 0.000 abstract 1
- 241001146210 Senecio scandens Species 0.000 abstract 1
- 241000246044 Sophora flavescens Species 0.000 abstract 1
- 241001671204 Stemona Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 210000003953 foreskin Anatomy 0.000 description 60
- 239000008280 blood Substances 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 33
- 238000011282 treatment Methods 0.000 description 33
- 201000010099 disease Diseases 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 208000003251 Pruritus Diseases 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 25
- 238000012360 testing method Methods 0.000 description 20
- 241000222122 Candida albicans Species 0.000 description 19
- 210000003899 penis Anatomy 0.000 description 19
- 238000005406 washing Methods 0.000 description 19
- 206010036624 Prepuce redundant Diseases 0.000 description 18
- 210000003859 smegma Anatomy 0.000 description 17
- 231100000614 poison Toxicity 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 15
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 14
- 230000001717 pathogenic effect Effects 0.000 description 14
- 206010023126 Jaundice Diseases 0.000 description 13
- 208000019802 Sexually transmitted disease Diseases 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 241000700199 Cavia porcellus Species 0.000 description 12
- 206010007134 Candida infections Diseases 0.000 description 11
- 201000004624 Dermatitis Diseases 0.000 description 11
- 208000004880 Polyuria Diseases 0.000 description 11
- 229940095731 candida albicans Drugs 0.000 description 11
- 230000035619 diuresis Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 206010015150 Erythema Diseases 0.000 description 10
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 208000001848 dysentery Diseases 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000003440 toxic substance Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 208000010668 atopic eczema Diseases 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 206010007247 Carbuncle Diseases 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 201000003984 candidiasis Diseases 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000002147 killing effect Effects 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 206010034878 phimosis Diseases 0.000 description 8
- 230000001568 sexual effect Effects 0.000 description 8
- 208000006820 Arthralgia Diseases 0.000 description 7
- 241000588653 Neisseria Species 0.000 description 7
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 241000222126 [Candida] glabrata Species 0.000 description 7
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 7
- 229960003321 baicalin Drugs 0.000 description 7
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 7
- 208000032343 candida glabrata infection Diseases 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 230000003628 erosive effect Effects 0.000 description 7
- 231100000321 erythema Toxicity 0.000 description 7
- 210000004392 genitalia Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 244000045947 parasite Species 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 210000001215 vagina Anatomy 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 239000012459 cleaning agent Substances 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 201000001881 impotence Diseases 0.000 description 6
- 230000001524 infective effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 208000037920 primary disease Diseases 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 5
- 208000008454 Hyperhidrosis Diseases 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 206010040943 Skin Ulcer Diseases 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 231100000019 skin ulcer Toxicity 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 4
- 206010063409 Acarodermatitis Diseases 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 241000192041 Micrococcus Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 241000588769 Proteus <enterobacteria> Species 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 241000447727 Scabies Species 0.000 description 4
- 208000033809 Suppuration Diseases 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 208000035861 hematochezia Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000002398 materia medica Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 201000007094 prostatitis Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000005687 scabies Diseases 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010004078 Balanoposthitis Diseases 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 3
- 208000001140 Night Blindness Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000972673 Phellodendron amurense Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- -1 antiinflammatory Substances 0.000 description 3
- 239000002221 antipyretic Substances 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000002894 beriberi Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000013219 diaphoresis Diseases 0.000 description 3
- 238000003113 dilution method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 208000017561 flaccidity Diseases 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 206010036596 premature ejaculation Diseases 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 201000009032 substance abuse Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 210000003905 vulva Anatomy 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010068625 Acquired phimosis Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 208000036119 Frailty Diseases 0.000 description 2
- 208000008899 Habitual abortion Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 241000517307 Pediculus humanus Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 208000024756 faint Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 208000009291 paraphimosis Diseases 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- XWBADQOPXPRKBX-FMIVXFBMSA-N 1-n,1-n-diethyl-4-n-[6-methoxy-2-[(e)-2-(4-nitrophenyl)ethenyl]quinolin-4-yl]pentane-1,4-diamine Chemical compound N=1C2=CC=C(OC)C=C2C(NC(C)CCCN(CC)CC)=CC=1\C=C\C1=CC=C([N+]([O-])=O)C=C1 XWBADQOPXPRKBX-FMIVXFBMSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010004074 Balanitis candida Diseases 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 244000089742 Citrus aurantifolia Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003716 antitrichomonal agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000000669 biting effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- NNBFNNNWANBMTI-UHFFFAOYSA-M brilliant green Chemical compound OS([O-])(=O)=O.C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 NNBFNNNWANBMTI-UHFFFAOYSA-M 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000001647 gastrula Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000011833 infective vaginitis Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008921 jie er yin Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000009306 yunnan baiyao Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种防治龟头炎的中药洗液,所述中药洗液中各种原料药的重量份数为:马齿苋10~20份,茵陈10~20份,青黛10~20份,苍术10~20份,七叶一枝花10~20份,百部10~20份,黄柏10~20份,苦参10~20份,地肤子10~20份,白藓皮10~20份,千里光10~20份,土茯苓10~20份,马齿苋10~20份,蛇床子10~20份,败酱草10~20份,黄芩10~20份,蒲公英10~20份,荆芥10~20份,川楝子10~20份。本发明具有消炎迅速,杀菌彻底,消炎除虫效果强。并且给药方便,药液易于制造,成本低廉等优点。本发明毒副作用小,使用方便,治愈时间短,治愈后不易复发。能达到标本兼治,以内养外,治愈后不易复发的男用洗液,也适合夫妻同房前共同使用。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物组份的保健品,特别涉及一种防治龟头炎的中药洗液及其制备方法。
背景技术
包皮龟头炎病因与包皮过长、包皮垢刺激、局部理化因素及各种感染有关。近年来,成人包皮龟头炎患者明显增多,这与人们性观念开放,婚外性行为增多,滥用各种清洁剂有关。有了不洁性行为后,增加了各种感染机会。为了避免染上性病,人们多自用一些外用消毒、消炎的清洁剂清洗消毒外阴。一些人为了消毒彻底,在阴茎包皮、龟头皮肤部位直接反复涂抹未按一定比例稀释的清洁剂原液。这样局部皮肤受到强烈的化学刺激出现红肿、渗出而出现急性炎症。急性炎症如果处理不当反复发作,最终可形成慢性包皮龟头炎。
包皮龟头炎分为包皮炎和龟头炎,由于常常同时出现故称为阴茎包皮龟头炎。这种炎症可以是感染性的和非感染性的,临床上以感染性的包皮龟头炎较多见。感染性的常由于不洁性交,感染了白色念珠菌、滴虫、衣原体、支原体、双球菌或其他细菌引起;非感染因素多是由于包皮过长,清洁不够,包皮和龟头之间的不洁之物,即包皮垢,便会堆积起来,刺激局部的包皮和粘膜发生炎症。
龟头炎对男性生殖健康危害很大,主要表现在:1、危害生殖系统健康:包皮龟头炎易导致前列腺炎、睾丸炎、附睾炎、输精管等器官的炎症。如果不能及时有效治疗,相互合并感染,对生殖健康会造成很大的伤害;2、引发泌尿系统疾病:包皮龟头炎还易引起泌尿系统的上行感染,多见于膀胱炎、肾炎、肾盂肾炎等,急性期发病处理不当可危及生命;3、导致性功能障碍:包皮龟头炎症期,龟头部性感应神经受炎症的损伤,使得男性在性生活中易早泄,进而导致阳痿的发生;4、造成不育症:由于包皮内隐藏的炎性分泌物在性交过程中和精液一起进入阴道,降低了精液质量,并且破坏精卵细胞,导致不育的发生;5、导致干燥性闭塞性龟头炎:为包皮龟头炎比较严重的一种病理损伤,不但破坏了包皮龟头的正常生理结构和美观,夫妻性生活质量也受到严重影响。
包皮龟头炎的病因:1、非感染因素包括局部创伤、摩擦、避孕药、肥皂和清洁剂等刺激,局部可表现为水肿性红斑、糜烂、渗液甚至出血,若继发细菌感染可化脓并形成溃疡面。患者疼痛明显,行动不便。临床上称之为急性浅表性龟头炎。2、念珠菌感染念珠菌是一种条件致病真菌,故念珠菌性龟头炎常继发于糖尿病,老年消耗性疾病以及大量抗生素或激素治疗之后,也可为原发性,多由配偶念珠菌阴道炎传来,龟头及冠状沟可有浅红色糜烂及薄壁脓疱,但局部常找不到念珠菌,可能为念珠菌引起的局部过敏反应所致。3、阿米巴原虫感染患者多先有包皮龟头炎病变,局部失去正常的屏障作用,继而由肠道阿米巴病传染而引起。局部糜烂、溃疡、组织坏死明显,分泌物直接涂片可找到阿米巴原虫。4、滴虫感染多因配偶患有阴道滴虫病而被传染。症状较轻,主要表现为龟头部起红斑丘疹、小水疱等。境界清楚、范围逐渐扩大,患者常感瘙痒。分泌物中可找到滴虫。此外,还有一些龟头炎病因不明确,但包皮过长,包皮垢刺激多与龟头炎的发生有关。故男性也应经常清洗下身,保持局部清洁、避免刺激。包皮过长者,可在炎症控制后进行包皮环切术。虽然包皮龟头炎的病原体较多而且发病复杂,但在实际临床中都会出现一些相似的症状。如包皮红肿、灼痛、排尿时加重、可有脓性分泌物自包皮口流出。如将包皮翻转,可见包皮内板和阴茎头充血、肿胀、重者可有浅小溃疡或糜烂,表现有脓液;或龟头起丘疹和红斑,逐渐扩大,边缘清楚,红斑上可见针头大小的小水疱,最后形成糜烂面;或龟头部起红斑丘疹、小水疱等。境界清楚、范围逐渐扩大,患者常感瘙痒。龟头炎可由于感染和非感染引起。由于不洁性交,感染了白色念珠菌、滴虫、衣原体、支原体及淋病双球菌,都可引起包皮龟头炎。非感染因素多是由于包皮过长,清洁不够,包皮和龟头之间的不洁之物,即包皮垢,便会堆积起来,刺激局部的包皮和粘膜发生炎症。
龟头炎在实际临床中由于患者对龟头炎的认识不足和医生的不规范、不得当治疗,也使得包皮龟头炎的反复发作危害加剧。1.容易被忽视而失治。由于包皮龟头炎发病率高,初期症状较轻,时好时坏,所以在日常生活中易被忽视,直到严重时就诊。到就诊时已经伴有并发症和合并症,对生殖健康系统已经造成了较大的损伤,所以一定要早检查早治疗。2.误认为性病而误治。当出现龟头炎时,多数患者认为是性病,自用外用消毒消炎的清洁剂,这样局部皮肤受到强烈的化学刺激出现红肿、渗出加剧了炎症反应,最终可形成慢性包皮龟头炎。而且也有些诊疗技术不佳的医生,或者因利益因素故意当作性病治疗,给患者身体和经济上造成很大的伤害。3.不规范的传统疗法效果有限。临床上不规范的治疗使得病情反复发作,同时由于包皮龟头炎病程长,抗生素的不规范使用和滥用,病菌容易产生耐药性等,使得传统的治疗达不到理想的效果,长期慢性炎症对泌尿生殖健康造成影响,出现前列腺炎,阳痿早泄等疾病。4.包皮过长等因素易被忽视。包皮过长也是包皮龟头炎发病和反复不愈的重要因素,如果不进行包皮过长的治疗,病菌和炎性分泌物容易藏匿与包皮里直接作用于病变部位或者新的组织结构,加剧病情或导致性的病灶,所以如果存在包皮过长需要及早治疗。
发明内容
本发明所要解决的技术问题在于,由于本病部位隐秘,很多人不愿去医院治疗;治疗不规范:临床上不规范的治疗使得病情反复发作,同时由于包皮龟头炎病程长,抗生素的不规范使用和滥用,病菌容易产生耐药性等,使得传统的治疗达不到理想的效果,长期慢性炎症对泌尿生殖健康造成影响,出现前列腺炎,阳痿早泄等疾病;临床以中医师随病证外方作汤剂口服,以及一些中药洗剂,但治疗效果均不甚理想,存在着可诱发耐药性、复发率高、用药不便、制剂困难等不足。现在迫切需要提供了一种见效快、副作用小、抑菌性强,效果迅速的的中药洗液,能有效解除患者的痛苦,治疗此病症。
为解决上述技术问题,本发明提供了一种防治龟头炎的中药洗液,所述中药洗液中各种原料药的重量份数为:马齿苋10~20份,茵陈10~20份,青黛10~20份,苍术10~20份,七叶一枝花10~20份,百部10~20份,黄柏10~20份,苦参10~20份,地肤子10~20份,白藓皮10~20份,千里光10~20份,土茯苓10~20份,马齿苋10~20份,蛇床子10~20份,败酱草10~20份,黄芩10~20份,蒲公英10~20份,荆芥10~20份,川楝子10~20份。
所述防治龟头炎的中药洗液,其所述中药洗液中各种原料药的重量份数可以为:马齿苋10~15份,茵陈10~15份,青黛10~15份,苍术10~15份,七叶一枝花10~15份,百部10~15份,黄柏10~15份,苦参10~15份,地肤子10~15份,白藓皮10~20份,千里光10~20份,土茯苓10~20份,马齿苋10~20份,蛇床子10~20份,败酱草10~20份,黄芩10~20份,蒲公英10~20份,荆芥10~20份,川楝子10~20份。
所述防治龟头炎的中药洗液,其所述中药洗液中各种原料药的重量份数还可以为:马齿苋10~20份,茵陈10~20份,青黛10~20份,苍术10~20份,七叶一枝花10~20份,百部10~20份,黄柏10~20份,苦参10~20份,地肤子10~20份,白藓皮10~15份,千里光10~15份,土茯苓10~15份,马齿苋10~15份,蛇床子10~15份,败酱草10~15份,黄芩10~15份,蒲公英10~15份,荆芥10~15份,川楝子10~15份。
为解决上述技术问题,本发明还提供一种防治龟头炎的中药洗液的制备方法,所述中药洗液的制备步骤包括:
a.将所述原料药放入粉碎机粉碎后过筛,
b.将过筛后剩下的颗粒物放入乙醇中加热回流提取2次;
c.再取上述乙醇提取后的药渣,加水加热回流提取2次;
d.将上述两种提取液合并浓缩;加高锰酸钾溶液搅拌均匀,紫外线消毒后罐装。
所述步骤a中,可以将所述原料药放入粉碎机粉碎后过100目细筛,使能通过100目筛的细粉量在达到30%,收集通过100目筛的原料细粉备用。
所述步骤b中,可以将过筛后剩下的粗颗粒物放入乙醇中加热回流提取2次,每次1~2小时,将2次提取液合并静置;
所述步骤c中,可以将上述乙醇提取过的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置。
所述步骤d中,可以将上述两种提取液合并,减压浓缩相对密度为80℃时1.37的滤液,回收乙醇,将所得滤液调整比重到1.60,加入过筛的细粉后搅匀;倒入0.5%高锰酸钾溶液中,搅拌均匀,用紫外线消毒后罐装。
为解决上述技术问题,本发明再提供一种防治龟头炎的中药洗液的制备方法,所述中药洗液剂的制备步骤进一步包括:将所述原料药混合,切碎,浸泡;将将浸泡好的原料药加热回流提取2次,每次1~2小时,将2次提取液合并静置;再将上述水提取过的药渣加5~8倍量60~70%乙醇加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述两种提取液合并,减压浓缩相对密度为80℃时1.35的滤液,回收乙醇,将所得滤液调整比重到1.60,减压得浸膏,加入0.5%高锰酸钾溶液浴搅拌均匀,混合成粘稠的液体,紫外线杀菌消毒后使用。
为解决上述技术问题,本发明也提供一种防治龟头炎的中药洗液的制备方法,所述中药洗液剂的制备步骤再一步包括:将所述原料药混合,切碎,浸泡加水煎煮2次,合并煎液,去除沉渣,上清液加入乙醇并过滤,滤液回收乙醇至净,最后用纯化水调整药液体积至每毫升药液相当于1g原药材,
药液为黄褐色至棕褐色液体,加入0.5%高锰酸钾溶液浴搅拌均匀,混合成粘稠的液体,紫外线杀菌消毒后使用。
本发明洗液采取外洗或坐浴,每次20~30mL,每日2次。一般以10d为1疗程,2~3个疗程后观察疗效。
与现有技术相比教,本发明具有杀菌彻底,消炎除虫效果强,抗炎、止痒效果好;并且给药方便,药液易于制造,成本低廉等优点;且安全,无毒副作用,使用方便,治愈时间短,治愈后不易复发。尤其适合夫妻同房前清洗私处。能创造较好的社会价值及经济利益,具有广阔的开发前景。
具体实施方式
包皮龟头炎是男性常见的疾病。我们发现此病如果治疗不当可引起包皮炎反复发作,致使包皮口、内板皮肤炎性微小裂口反复发生。经多次愈合而引起疤痕增生,最终导致包皮内板炎性增厚或与龟头皮肤粘连,包皮口形成肥厚性狭窄环。阴茎勃起时龟头受包皮龟头炎是指包皮内板与阴茎头的炎症。正常包皮腔内分泌的一种类脂物质,在包皮过长或包茎时,此类物质可积聚成包皮垢刺激包皮和阴茎头引起包皮龟头炎。包皮龟头炎如果久治不愈则可导致,继发性包茎,尿道外口狭窄,前尿道狭窄,前列腺炎,性功能障碍,男性不育等。
对于龟头炎的预防治疗,经常清洗包皮和阴茎头,保持包皮腔内清洁和干燥,包皮炎是完全可以预防的。平时应注意养成良好的卫生习惯,对包皮过长或包茎(包皮不能翻转)者行包皮环切术等都有很好预防作用,若该病一旦发现,在患处将包皮翻转用高锰酸钾液浸泡清洗,适当应用抗生素,多在数天内治愈;若较严重则需在医生指导下进行有效治疗。包皮垢还是细菌繁殖的场所,残留尿液和包皮垢混合形成了细菌的天然培养基地,容易引起包皮和阴茎头发炎。发生在尿道口的炎症,愈合后可引起尿道口狭小,造成排尿困难。另外,约有85%-95%的患者有包茎或包皮过长病史。这可能也是包皮垢导致的。长期没有清理包皮垢,会引起包皮粘连,令包皮翻转时感到疼痛,严重的还会使包皮无法翻转上去。包皮过长带来的包皮垢使得阴茎包皮粘连,在过性生活是会因为包皮翻转困难而感觉疼痛。而且包皮垢还会把细菌带到脆弱敏感的阴道里。使得你的性伴侣患上这等疾病。所有这些不好的影响都与包皮过长带来的过多的包皮垢有关。解决包皮包茎和包皮垢带来的危害的一劳永逸的办法是进行一次简单的包皮环切手术,但是如果不想进行包皮环切手术,又想保持健康的身体,最好最简单的办法经常清洗包皮,清理包皮垢。包皮过长如强行上翻后而不能复位时,可造成包皮嵌顿,因为可能造成龟头坏死,必须立刻到医院寻求帮助。清洗包皮垢时,由于由于包皮内板比外板薄润,对化学清洁剂比较敏感,所以不能使用刺激性的洗涤剂,清水冲洗即可。性质较温和的香皂、淋浴露也可以。
本病一方面与内因:肝、肾、脾功能失常关,肝脉绕阴器,又主藏血,为风木之脏;肾主藏精,主生殖,开窍于二阴;脾主运化水湿。如若肝经湿热或肝郁脾虚化火生湿,湿热之邪随经下注,蕴结阴器故而阴痒;或肝肾不足,精血亏虚,生风化燥,阴部肌肤失养,不荣而痒;另外一方面与外因感染湿邪病虫有关,因摄身不慎,致湿邪病虫侵入,虫扰阴部,发为阴痒。按照传统中医理论,由内因所致者以内服药调整功能为主,而因外感病虫所致者或辅以外治或以外治为主要手段。
由于感染湿邪病虫所致之阴痒、带下者多表现为肝经湿热,因而治疗应以清热除湿、杀虫止痒为原则。本病主要是因湿热蕴结,虫蚀阴中所致湿热之邪有内外之分。如久居湿地等致湿邪外侵,郁而化热,或经期、产后,湿热邪毒乘虚而入,此为外感湿热。若素体脾气虚弱,或肝气郁结,木克脾土,脾失健运,水湿内留,停注下焦,蕴而化热,则为内生湿热。湿热蕴结,韧带不固,小便色黄。下焦湿热,膀优失约则并发淋证;湿邪浸淫日久成毒,或感染热毒邪气,热盛迫血妄行,或湿毒腐蚀肌肤,则可见带下脓血,或见"阴蚀"、"阴疮"。湿腐生虫,或摄生不慎,虫邪直犯阴器,虫蚀阴中则阴痒,阴中灼痛本病虽病在阴器,但每与肝脾等脏腑有关。多因湿邪为病。显然,引发感染性阴道炎的原因应属后者。
由于包皮龟头炎发病率高,初期症状较轻,时好时坏,所以在日常生活中易被忽视,直到严重时就诊。到就诊时已经伴有并发症和合并症,对生殖健康系统已经造成了较大的损伤,所以一定要早检查早治疗。当出现龟头炎时,多数患者认为是性病,自用外用消毒消炎的清洁剂,这样局部皮肤受到强烈的化学刺激出现红肿、渗出加剧了炎症反应,最终可形成慢性包皮龟头炎。而且也有些诊疗技术不佳的医生,或者因利益因素故意当作性病治疗,给患者身体和经济上造成很大的伤害。
地肤子清热利湿,祛风止痒。用于小便涩痛、阴痒带下、风疹、湿疹、皮肤瘙痒。《药性论》:"与阳起石同服,主丈夫阴痿不起,补气益力;治阴卵癀疾,去热风,可作汤沐浴。"地肤子煎剂2g/kg给家兔灌胃,6小时内尿中氯化物增加127.1%~131.6%,但总尿量无变化.有报告指出,地肤子对大白鼠尿量及尿钠排出均有影响。
黄柏清热燥湿,泻火除蒸,解毒疗疮。用于湿热泻痢,黄疸,带下,热淋,脚气,痿辟,骨蒸劳热,盗汗,遗精,疮疡肿毒,湿疹瘙痒。盐黄柏滋阴降火。用于阴虚火旺,盗汗骨蒸。《中国药典》载黄柏清热燥湿之力,与黄芩、黄连相似,但以除下焦之湿热为佳。
苦参性苦,寒。归心、肝、胃、大肠、膀胱经清热燥湿,杀虫,利尿。用于热痢,便血,黄疸尿闭,赤白带下,阴肿阴痒,湿疹,湿疮,皮肤瘙痒,疥癣麻风;外治霉菌性阴道炎,常与黄柏结合使用,是治疗阴道炎的外用妇科良药。
百部性味甘苦,微温。《别录》:微温。《药性论》:味甘,无毒。《日华子本草》:味苦,无毒。性味甘、苦,微温。归肺经。功能主治润肺下气止咳,杀虫。用于新久咳嗽,肺痨咳嗽,百日咳;外用于头虱,体虱,蛲虫病,阴部骚痒。
白藓皮祛风,燥湿,清热,解毒。治风热疮毒,疥癣,皮肤痒疹,风湿痹痛,黄疸。《本经》:主头风,黄疸,咳逆,淋沥,女子阴中肿痛,湿痹死肌,不可屈伸、起止、行步。
土茯苓性味:甘淡,平。归经:肝经;胃经;脾经。功能:解毒,除湿,利关节。主治:治梅毒,淋浊,筋骨挛痛,脚气,疔疗疮,痈肿,瘰疬。
黄芩有清热燥湿,凉血安胎,解毒功效。主治温热病、上呼吸道感染、肺热咳嗽、湿热黄胆、肺炎、痢疾、咳血、目赤、胎动不安、高血压、痈肿疖疮等症。黄芩的临床应用抗菌比黄连还好,而且不产生抗药性。我们借助广谱抗菌作用强的特点,用在真菌培养杂菌感染特厉害,用黄芩提取液效果很好。《本草经疏》:黄芩,其性清肃,所以除邪:味苦所以燥湿;阴寒所以胜热,故主诸热。诸热者,邪热与遍热也,黄疸、肠僻、泄痢,皆湿热胜之病也,析其本,则诸病自瘳矣。苦寒能除湿热,所以小肠利而水自逐,源清则流洁也。血闭者,实热在血分,即热人血室,令人经闭不通,湿热解,则荣气清而自行也。恶疮疽蚀者,血热则留结,而为痈肿渍烂也:火疡者,火气伤血也,凉血除热,则自愈也。黄芩有抗变态反应及抗炎作用:黄芩所含黄芩甙与黄芩素能明显抑制致敏豚鼠离体小肠与离体气管对抗原所产生的过敏性收缩反应,对豚鼠与小鼠的被动全身性变态反应以及豚鼠被动性皮肤变态反应,黄芩甙与黄芩素亦有抑制作用。黄芩有解热作用,多数试验证明,黄芩的有效成份黄芩甙元有解热作用。黄芩有解毒作用,黄芩甙有明显的解毒作用,这可能是由于在β-葡萄糖醛酸甙酶的作用下,黄芩甙分解出葡萄糖醛酸,并与多种毒物结合所致。黄芩甙10毫克能提高士的宁的LD50达2.5倍,并且使四氯化碳中毒小鼠的肝糖原含量增多。
败酱草性味苦平,具有清热解毒、排脓破瘀的功效。能医肠痈、下痢、赤白带下、产后瘀滞腹痛、目赤肿痛。入胃、大肠、肝经。主治清热解毒,消痈排脓,活血行瘀。用于肠痈、肺痈及疮痈肿毒,实热瘀滞所致的胸腹疼痛,产后瘀滞腹痛等症。
千里光,又名九里明、九里光。拉丁名称Herba Senecionis Scandentis。是一种中草药,生于山坡、疏林下、林边、路旁、沟边草丛中。其性寒,味苦,具有清热解毒,明目,止痒等功效。多用于风热感冒、目赤肿痛、泄泻痢疾、皮肤湿疹疮疖。《本草拾遗》:主疫气,结黄,疟瘴,盅毒,煮服之吐下,亦捣敷疮、虫蛇犬等咬伤处。
马齿苋热毒痢疾、肠炎、痈肿疮毒、蛇虫咬伤。性味酸;性寒。归经:大肠;肝经。清热解毒,利水去湿,散血消肿,除尘杀菌,消炎止痛,止血凉血。主治痢疾,肠炎,肾炎,产后子宫出血,便血,乳腺炎等病症。散血消肿,利肠滑胎,解毒通淋,治产后虚汗。马齿苋对痢疾杆菌、伤寒杆菌和大肠杆菌有较强的抑制作用,可用于各种炎症的辅助治疗,素有“天然抗生素”之称。《开宝本草》:“服之长年不白。治痈疮,杀诸虫。生捣汁服,当利下恶物,去白虫。”《本草纲目》:“散血消肿,利肠滑胎,解毒通淋,治产后虚汗。”
蒲公英植物体中含有蒲公英醇、蒲公英素、胆碱、有机酸、菊糖等多种健康营养成分,有利尿、缓泻、退黄疸、利胆等功效。蒲公英同时含有蛋白质、脂肪、碳水化合物、微量元素及维生素等,有丰富的营养价值,可生吃、炒食、做汤,是药食兼用的植物。蒲公英植物体中含有蒲公英醇、蒲公英素、胆碱、有机酸、菊糖等多种健康营养成分,有利尿、缓泻、退黄疸、利胆等功效。蒲公英同时含有蛋白质、脂肪、碳水化合物、微量元素及维生素等,有丰富的营养价值。其中含有的胡萝卜素和C及矿物质,对消化不良、便秘都有改善的作用。另外叶子还有改善湿疹、舒缓皮肤炎的功效,根则具有消炎作用,花朵煎成药汁可以去除雀斑。
蛇床子性辛、苦,温;有小毒。归肾经。主治温肾壮阳,燥湿,祛风,杀虫。用于阳痿,宫冷,寒湿带下,湿痹腰痛;外治外阴湿疹,妇人阴痒;阴囊湿疹,是妇科外用良药。《本草经疏》载:蛇床子,味苦平;《别录》辛甘无毒;今详其气味,当必兼温燥,阳也。故主妇人阴中肿痛,男子阴痿湿痒,除痹气,利关节,恶疮。《别录》温中下气,令妇人子服热,男子阴强,令人有子。盖以舌能除湿,温能散寒,辛能润肾,甘能益脾,故能除妇人男子一切虚寒湿所生病。寒湿既除,则病去,性能益阳,故能已疾,而又有补益也。
马齿苋全草供药用,有清热利湿、解毒消肿、消炎、止渴、利尿作用;种子明目。现代研究,马齿苋还含有丰富的SL3脂肪酸及维生素A样物质:SL3脂肪酸是形成细胞膜,尤其是脑细胞膜与眼细胞膜所必需的物质;维生素A样物质能维持上皮组织如皮肤、角膜及结合膜的正常机能,参与视紫质的合成,增强视网膜感光性能,也参与体内许多氧化过程。马齿苋全株入药具有解毒、抑菌消炎、利尿止痢、润肠消滞、去虫、明目和抑制子宫出血等药效;外用可以治丹毒、毒蛇咬伤等症。
茵陈性微寒,味辛、苦功能主治清湿热,退黄疸。用于黄疸尿少、湿疮瘙痒、传染性黄疸型肝炎。茵陈的功效。清热利湿;退黄.主治:黄疸;小便不利;湿疮瘙痒等.药理学研究有利胆,保护肝功能,解热,抗炎,降血脂,降压,扩冠等作用,当然,这只是西医学提取茵陈成分做出来的研究,临床应用上效果如何不好判定。茵陈用量过大可引起头晕,恶心,腹泻,上腹部不适,急性肝胆损伤,亦有心律不齐的报导.但是治疗剂量的茵陈一般不会造成严重的损伤。茵陈有显著的保肝作用,对甲,乙型肝炎,黄疸型肝炎,有显著的疗效.有利胆,促进胆汁分泌,增加胆汁中胆酸和胆红素排出的作用.能增加心脏冠脉血流量,改善微循环,并有降血压,降血脂,抗凝血,利尿解热平喘,驱除蛔虫及抑制多种致病性皮肤真菌与细菌的作用。
青黛具有清热,凉血,解毒的功效,且性甘,平,无毒,入肝、肺、胃经。清热解毒,凉血,定惊,用于温毒发斑,血热吐衄,胸痛咳血,口疮,痄腮,据《要药分剂》载:除热解毒,兼能凉血。《雷公炮制药性解》载:“入肝,脾二经。”
苍术燥湿健脾,祛风散寒,明目。用于脘腹胀满,泄泻水肿,脚气痿躄,风湿痹痛,风寒感冒,夜盲。苍术具有燥湿健脾,祛风湿的功效。主治湿阻中焦,风寒湿痹,脚膝肿痛,痿软无力,雀目夜盲。《珍珠囊》日:“能健胃安脾,诸湿肿非此不能除。”《本草纲目》曰:“治湿痰留饮……及脾湿下流,浊沥带下,滑泻肠风。”《新修本草》称其能“利小便”。
七叶一枝花,拉丁学名Paris polyphylla Sm.归心经、肝经、肺经、胃经、大肠经。败毒抗癌、消肿止痛、清热定惊、镇咳平喘。治痈肿肺痨久咳、跌打损伤、蛇虫咬伤、淋巴结核、骨髓炎等症,是云南白药的主要成分之一。对亚洲甲型流感病毒有较强的抑菌作用,对痢疾杆菌、副伤寒杆菌、沙门氏菌、副大肠杆菌、绿脓杆菌、金黄色葡萄球菌、溶血性链球菌、脑膜炎双球菌等均有抑菌作用。
荆芥味平,性温,无毒,清香气浓。荆芥为发汗,解热药,是中华常用草药之一。能镇痰、怯风、凉血。治流行感冒,头疼寒热发汗,呕吐。祛风;解表;透疹;止血。主感冒发热;头痛;目痒;咳嗽;咽喉肿痛;麻疹;痈肿;疮疥;衄血;吐血;便血;崩漏;产后血晕。用于感冒,头痛,麻疹,风疹,疮疡初起。炒炭治便血,崩漏,产后血晕。《本经》:主寒热,鼠瘘,瘰疬生疮,破结聚气,下瘀血,除湿痹。《药性论》:治恶风贼风,口面歪邪,遍身顽痹,心虚忘事,益力添糟。主辟邪毒气,除劳,治丁肿;取一握切,以水五升,煮取二升,冷分二服,主通利血脉,传送五脏不足气,能发汗,除冷风;又捣末和醋封毒肿。
川楝子性寒,味苦,是行气药的一种。主要入肝经,疏泄肝热,行气止痛,有除湿热、清肝火、止痛、杀虫的功能。除湿热,清肝火,止痛,杀虫。治热厥心痛,胁痛,疝痛,虫积腹痛。《本经》:"主温疾、伤寒太热烦狂,杀三虫疥窃,利小便水道。"
实施例1:本发明洗液制备步骤为:将所述原料药马齿苋1000g,茵陈1000g,青黛1000g,苍术1000g,七叶一枝花1000g,百部1000g,黄柏1000g,苦参1000g,地肤子1000g,白藓皮1000g,千里光1000g,土茯苓1000g,马齿苋1000g,蛇床子1000g,败酱草1000g,黄芩1000g,蒲公英1000g,荆芥1000g,川楝子1000g。放入粉碎机粉碎后过100目细筛,使能通过100目筛的细粉量在达到30%,收集通过100目筛的原料细粉备用。将过筛后剩下的粗颗粒物放入乙醇中加热回流提取2次,每次1~2小时,将2次提取液合并静置。将上述乙醇提取过的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置。将上述两种提取液合并,减压浓缩相对密度为80℃时1.35的滤液,回收乙醇,将所得滤液调整比重到1.06,加入0.5%高锰酸钾溶液浴搅拌均匀,混合成粘稠的液体,紫外线杀菌消毒后使用。
实施例2:本发明洗液的制作过程还可以为:将原料药马齿苋1300g,茵陈1300g,青黛1200g,苍术1300g,七叶一枝花1400g,百部1200g,黄柏1300g,苦参1300g,地肤子1400g,白藓皮1200g,千里光1100g,土茯苓1200g,马齿苋1300g,蛇床子1200g,败酱草1300g,黄芩1100g,蒲公英1300g,荆芥1200g,川楝子1300g。先将所述原料药粉碎成粗粉,再进一步粉碎,过100目筛,使能通过100目筛的细粉量在达到30%,收集通过100目筛的细粉得细粉a;再将不能通过100目筛的粗粉投入多功能提取罐提取两次,第一次加8-10倍量乙醇煎煮1-2小时,第二次加4-8倍量水煎煮1-2小时,合并两次煎液,过滤得滤液;加热浓缩至糊状,成粗颗粒提取液b,加入制备的细粉a放入粗颗粒提取液b中,加入0.5%高锰酸钾溶液浴搅拌均匀,混合成粘稠的液体,紫外线杀菌消毒后使用。
实施例3:本发明洗液的制作过程也可以为:将马齿苋1400g,茵陈1300g,青黛1200g,苍术1100g,七叶一枝花1400g,百部1200g,黄柏1300g,苦参1300g,地肤子1400g,白藓皮1200g,千里光1100g,土茯苓1400g,马齿苋1300g,蛇床子1200g,败酱草1200g,黄芩1100g,蒲公英1400g,荆芥1300g,川楝子1300g。混合,切碎,浸泡加水煎煮2次,合并煎液,去除沉渣,上清液加入乙醇并过滤,滤液回收乙醇至净,最后用纯化水调整药液体积至每毫升药液相当于1g原药材,药液为黄褐色至棕褐色液体,加入0.5%高锰酸钾溶液浴搅拌均匀,混合成粘稠的液体,紫外线杀菌消毒后使用。
本洗液采取外洗或坐浴,每次20~30mL,每日2次。一般以10d为1疗程,2~3个疗程后观察疗效。
药理学毒性试验:
一、抗菌实验
体内抗菌试验结果表明,本发明洗液对大肠杆菌和变形杆菌的动物有明显的保护作用,可减病情的发展,降低动物的死亡率;体外抗菌实验结果表明,本发明对泌尿系统感染的细菌有不同程度的抑菌和杀菌作用;对实验性大鼠前列腺炎的影响实验结果表明,本发明可抑制细菌感染后泌尿腺体的增重,减缓病情的发展,抑制前列腺组织的病理形态变化;给药后2-5小时可以使动物的尿量明显增加;对新鲜酵母引起的家兔体温升高给药后5小时明显的降温作用;对二甲苯引起的动物耳壳肿胀及对棉球肉芽肿组织有明显的抑制作用,并抑制毛细血管通透性的增加;对化学物质刺激动物腹膜或温度刺激动物体表引起的疼痛有一定的抑制作用。
试验结果表明:本发明中药洗液实验安全。该药对乙型链球菌、金黄色葡萄球菌、大肠杆菌的最小抑制浓度为1∶150,淋球菌为1∶150,白色念珠菌为1∶300,对1∶20稀释度时的杀灭时间为5分钟,1∶50时为10分钟,1∶100时为20分钟,1∶200时为40分钟,1∶400时为8小时。
二、动物急性毒性试验研究:
当本发明洗液采用直肠给药途径,测得小鼠的一日最大给药量为62.7g/kg(以药粉计),约为拟临床人用量的1567.5倍(人以60kg计),大鼠的一日最大给药量62.7g/kg(以药粉计),约为拟临床人用量的1567.5倍。实验动物均连续观察一周,其外观体征、精神状态、饮食、饮水、粪便等均未见明显异常。实验结束时,动物均健康存活,体重增加。
三、动物长期毒性试验研究:
本试验设本发明药物高、中、低洗液剂量组和基质对照组、空白对照组,采用直肠给药途径给予大鼠,给药剂量分别为3.2、2.4和1.6g/kg(以药粉计),相当于拟临床病人用量[0.04g(药粉)/kg]的80、60和40倍,连续给药2个月,在给药过程中,各给药组及基质组大鼠的体重、饮食量、外观体征、行为活动、精神状态、毛色、粪便性状与空白对照组比较,无明显差异(P>0.05),动物体重增长值和主要脏器系数与空白对照组比较差异不显著(P>0.05),血液学和血液生化指标检查结果给药组个别指标与空白对照组比较差异显著(P<0.05),但恢复期结束后有差异的血液学和血液生化指标均已恢复正常,其他指标与空白对照比较差异不显著(P>0.05),给药期和恢复期组织学检查高剂量组动物主要脏器与空白对照组比较未见明显差异,未见迟缓性毒性出现。
四、动物局部刺激试验:
本发明洗液对豚鼠皮肤过敏试验和大鼠直肠用药刺激性试验。
结果表明:皮肤过敏试验,高剂量组0.8g(药粉)/kg、低剂量组0.1g(药粉)/kg,分别相当于拟临床人用量[0.04g(药粉)/kg]的20倍、2.5倍,经皮肤给药,均未见动物产生变态反应;直肠用药刺激性试验高剂量组5.0g(药粉)/kg,低剂量组3.2g(药粉)/kg,分别相当于拟临床人用量的125、80倍,在规定的时间内观察直肠粘膜均无充血、水肿等现象,病理组织学检查与空白对照组比较无明显差异,未见出现明显的刺激性反应,每组留存的部分动物其全身状况,体重、呼吸、循环、中枢神经系统及四肢活动等,均无明显异常反应。
五、阴道粘膜刺激试验结果
1.试验方法:
实验动物检疫3天后,选用18只上述健康家兔,随机分为三组,每组各6只,分别为:空白对照、赋形剂对照、本发明洗液剂组(按应用液5倍浓度)。分别用适当大小的灭菌棉条浸以灭菌生理盐水和受试物置于赋形剂对照组和受试物组动物阴道内,与阴道粘膜接触6小时,24小时后处死动物。取出局部阴道组织,观察病变情况。
2、试验结果:阴道粘膜刺激试验结果
六、皮肤过敏试验结果
用本发明洗液,进行诱导和激发接触试验,在24小时和48小时后观察试验小鼠,均不见皮肤有红斑及水肿等现象,与阴性对照组无差异。结果表明,该膏剂对皮肤反应强度近于零,即无皮肤变态反应。
试验结果表明:本发明中药洗液实验安全。该药对乙型链球菌、金黄色葡萄球菌、大肠杆菌的最小抑制浓度为1∶150,淋球菌为1∶150,白色念珠菌为1∶300,对1∶20稀释度时的杀灭时间为5分钟,1∶50时为10分钟,1∶100时为20分钟,1∶200时为40分钟,1∶400时为8小时。
药效学试验
受试药物:本发明外用洗液剂,可加水制成浓度不一的洗液。阳性药物为洁尔阴洗液。受试动物:ICR品系小白鼠,SD品系大鼠、豚鼠,雌雄各半或单雄性,由山东大学生物系提供,体重:小鼠18~22g、大白鼠220~300g、豚鼠340~420g。动物饲养条件:实验室空调控温,室温25~28℃,相对湿度45%~75%。
(一)体外抗菌试验
培养基:肉汤培养基、肉汤琼脂培养基、血平板、巧克力平板;菌种:选用大肠杆菌、绿脓杆菌、金黄色葡萄球菌、白色念珠菌、变形杆菌、淋球菌、丙型链球菌、卡他球菌等菌种;方法:稀释法,将本发明洗剂I号和II号0.1g/mL用肉汤自1∶5至1∶160作倍比稀释,每管含药液2ml,第9管为无药对照,每管中加入稀释菌液1滴,37℃孵育18h,肉眼观察结果,含药最低浓度尚呈明显不混浊管为该药的最小抑菌浓度(MIC)。淋球菌在肉汤中生长不良,改用巧克力平板稀释法测最小抑菌浓度。如下表:
菌株 | 最低抑菌浓度(MIC)(mg/ml) |
白色念珠菌 | 4.135 |
淋球菌 | 11.8 |
丙型链球菌 | 27 |
绿脓杆菌 | 5.95 |
大肠杆菌 | 51 |
卡他球菌 | 23 |
金黄色葡萄球菌 | 6.18 |
结果表明本发明洗剂均对大肠杆菌、绿脓杆菌、金黄色葡萄球菌、白色念珠菌、变形杆菌、卡他球菌、丙型链球菌的最小抑菌浓度为5mg/ml,淋球菌为10mg/ml。对大肠杆菌、绿脓杆菌、金黄色葡萄球菌、白色念珠菌、变形杆菌、卡他球菌、丙型链球菌、淋球菌均有明显的抑菌作用。
2、本发明对组胺致豚鼠阴道瘙痒的影响
(1)、受试物及药品:(1)、供试品为本发明药物洗液,(2)、复方黄柏洗液;赣卫消证字(2004)第0237号(3)、妇炎洁洗液,市售。
(2)、动物:豚鼠,普通级,体重150~250g,山东大学生物实验动物室提供
取豚鼠50只,每只豚鼠砂纸擦伤阴道皮肤,面积约1cm2,随后动物随机分组:(1)空白对照组(10ml/kg,ig);(2)复方黄柏洗液(4mg/kg,ig);(3)妇炎洁组(1g/kg,ig);(4)本发明药物洗液剂低剂量组(2.3g/kg,ig);(5)本发明药物外用洗液高剂量组(4.5g/kg,ig)。30分钟后,在阴道创面滴0.01%组胺液,此后每隔3分钟依0.01%、0.02%、0.03%、0.04%……递增浓度,每次均为0.05ml/只,直致出现豚鼠回头舔阴道,以最后出现豚鼠回头舔阴道时所给予的组胺总量为致痒阈。
表2本发明药物对组胺所致豚鼠阴道瘙痒反应的影响(X±SD)
组别 | 剂量 | 动物数 | 致痒阈(组胺总量,μg) |
空白对照组 | 10 | 57.0±95.1 | |
妇炎洁组 | 4mg/kg | 10 | 137.9±47.4*** |
复方黄柏洗液 | 1g/kg | 10 | 131.0±106.7** |
本发明药物低剂量组 | 2.3g/kg | 10 | 125.0±102.4* |
本发明药物高剂量组 | 4.5g/kg | 10 | 108.3±86.8*** |
与空白对照组作t检验,*P>0.05,**P<0.05,***P<0.01
结果表明,本发明药物4.5g/kg剂量组可明显提高致痒阈,见表2。与空白对照组比较有显著性差异(P<0.01)。
临床资料
男性包皮龟头炎是临床上的常见病、多发病,念珠菌感染是其中最常见的病因。随着广谱抗生素及皮质激素的广泛应用和性传播疾病的增加,男性包皮龟头炎发病率日趋上升。为了解念珠菌性包皮龟头炎的菌种分布及菌株对三种常用抗真菌药物的敏感性。本院对100例直接镜见阳性的男性包皮龟头炎患者的标本进行分离培养,并对部分分离株进行了体外抗真菌药物敏感性试验。现报告如下。
1、资料与方法
1.1临床资料:100例包皮龟头炎患者均来自本院2009年9月~2012年9月皮肤、性病科门诊的患者。所有患者包皮或龟头部均具有不同程度的红斑、丘疹、伴或不伴瘙痒症状。年龄20~65岁,平均34岁:病程3天~1个半月。对照组50人,治疗组50人,两组人选无差异性。
1.2试剂
1.2.1主要试剂:科玛嘉念珠菌显色培养基(上海科玛嘉微生物技术有限公司);RPHll640粉末培养基(Grand island N.Y.U.S.A):MOPS[3-(n-吗啡啉丙磺酸)(Sigma chemical co)]。
1.2.2抗真菌药物:伊曲康唑由天津医药工业研究院提供,批号:001201,含量98.8%;氟康唑由上海三维康制药有限公司提供,批号:990805,含量99.55%;特比萘芬由山东齐鲁制药公司提供,批号:991105,含量99.0%。
1.2.3质控株:近平滑念珠菌ATCC22019。
1.3方法
1.3.1标本采集和分离培养,用蘸取生理盐水的柳叶刀刮取包皮、龟头冠状沟处的分泌物和鳞屑做直接镜见,并同时接种于科玛嘉念珠菌显色培养基上于37℃培养。
1.3.2菌种鉴定:通过念珠菌在科玛嘉念珠菌显色培养基呈现的颜色来进行识别鉴定:翠绿色为白念珠菌;紫色为光滑念珠菌;粉红色为克柔念珠菌;蓝色为热带念珠菌。
1.3.3药敏试验:参照美国国家临床实验室标准化委员会推荐的M27-A(液基微量稀释法参考方案)进行药敏测定。
1.3.4培养基制备:RPMll640培养基的配制:含10.4gRPUll640粉末、34.53gMOPS[3-(n-吗啡啉丙磺酸)(Sigma chemical co)],加900ml蒸馏水溶解后,用lM NaOH调节pH至7.0,补充蒸馏水至1000ml,0.2μm滤器(Gelman Laboratory U.S.A)过滤,4℃保存。
1.3.5.药物贮存液制备:所有药物贮存液浓度均设为1280μg/ml,除氟康唑用蒸馏水溶解外,其余药物均用DMSO溶解,药物贮存液置无菌聚乙烯小瓶-70℃保存。
1.3.6.微量药敏板制备:药物贮存液用RPHll640培养基稀释,氟康唑贮存液稀释10倍,其余药物贮存液稀释40倍。第1孔加200μl稀释后药液,第2~12孔每孔加相应培养基100μ1,从第1孔吸100μl,加入第2孔,充分混匀后,自第2孔吸取100μl加入第3孔,…,依次递倍稀释至第10孔,吸取100μl丢弃。使氟康唑起始浓度为128μg/ml,终末浓度为0.25μg/ml:其余药物起始浓度为32μg/ml,终末浓度为0.06μg/ml。第11孔作生长对照,第12孔作空白对照。加毕后药敏板置-70℃保存。
1.3.7菌液制备及接种培养:所有菌株均传代接种2次,以纯化菌落并增强活力,用无菌生理盐水制成(1~5)*106CFU/ml菌悬液,再用RPMll640培养基稀释至(1~5)*103CFU/ml。取出冷冻药敏板,待融后依次从第1~11孔加入菌接种液100μl,第12孔不加。接种后35℃孵育。
1.3.8结果判读:每天观察受试菌株生长情况,于48小时读取结果,视觉法判定终点。
2.治疗结果
2.1药物治疗:对照组口服伊曲康唑或氟康唑,每日2片,每天用高锰酸钾0.5%溶液清洗龟头患处。10天为一个疗程。
治疗组口服甲硝锉片,每日2片,用本发明洗液护理。药用:马齿苋13g,茵陈12g,青黛12g,苍术12g,七叶一枝花13g,百部12g,黄柏13g,苦参13g,地肤子14g,白藓皮12g,千里光11g,土茯苓12g,马齿苋13g,蛇床子12g,败酱草13g,黄芩11g,蒲公英12g,荆芥12g,川楝子13g。本洗液采取外洗或坐浴,每次20~30mL,每日2次。一般以10d为1疗程,2~3个疗程后观察疗效。
2.2治疗结果见表1.
组别 | 人数 | 痊愈 | 有效 | 显效 | 无效 | 总有效率 |
对照组 | 50 | 23 | 10 | 11 | 7 | 86% |
治疗组 | 50 | 38 | 6 | 4 | 2 | 96 |
显示本发明洗液配合抗菌类药物治疗龟头炎效果绝佳。
3讨论
近年来,随着广谱抗生素的广泛应用,由念珠菌引起的包皮龟头炎有逐渐增多的趋势,国外报道约占所有包皮龟头炎的1/3。以直接镜检阳性为诊断标准,结果显示念珠菌性包皮龟头炎占所有包皮龟头炎的15.44%。但值得注意的是,念珠菌作为外生殖器部位的皮肤正常菌群,判断其是否属于致病真菌尤为重要,直接镜检见到由念珠菌形菌丝和侧生芽生孢子组成的假菌丝体则归为致病菌。否则,如果仅以显微镜下见到孢子便予以治疗,可能导致菌群失调和耐药。因此,真菌学检查特别是直接镜检非常重要。
就本次实验分离的念珠菌菌种分布结果显示,白念珠菌占绝大多数(68.70%)。但值得注意的是,从镜检阴性患者分离出的念珠菌中,光滑念珠菌占了绝大多数(67.42%),可能说明,光滑念珠菌往往作为寄居状态存在于男性外生殖器上。有研究报道,光滑念珠菌是复发性外阴阴道念珠菌病的主要病原菌之一,而且光滑念珠菌等非白念珠菌对唑类药物耐药性逐年上升,意味着应重视光滑念珠菌,是否提示不管光滑念珠菌在男性外生殖器部位是致病状态还是寄居状态均应治疗,值得探讨。
龟头炎是男性比较常见的皮肤黏膜炎症。本组病例<30岁占50%,<50岁占84.62%,说明发病与年龄有关,性活跃期的男性多见。复发病例占首诊者的46.15%,不少人数月、数年来多次复发及治疗,说明近一半患者有复发倾向,故本病治疗后要注意防治复发。
本病侵犯部位以包皮内层、冠状沟最多见,为88.46%,从解剖关系上看,此层与阴茎头间构成狭窄裂隙,易受包皮垢、尿道炎性分泌物等的刺激,即使是龟头先发病,亦易蔓延到此处。应嘱患者做外阴清洁时要特别注意清洁包皮内层。根据临床表现,急性浅表性包皮龟头炎最为常见,占75.00%,以典型的念珠菌性包皮龟头炎形式出现者占第二位,为23.08%,治疗上要有针对性。
本组病例包皮过长、包茎占40.38%,包皮垢21.15%,后者亦多见于包皮过长、包茎者,且念珠菌检测阳性病例中包皮过长和(或)包茎占63.64%,说明后者是念珠菌感染的先决条件之一,故建议在炎症控制后做包皮环切术,尤其是复发病例。
Claims (10)
1.一种防治龟头炎的中药洗液,其特征在于,所述中药洗液中各种原料药的重量份数包括:马齿苋10~20份,茵陈10~20份,青黛10~20份,苍术10~20份,七叶一枝花10~20份,百部10~20份,黄柏10~20份,苦参10~20份,地肤子10~20份,白藓皮10~20份,千里光10~20份,土茯苓10~20份,马齿苋10~20份,蛇床子10~20份,败酱草10~20份,黄芩10~20份,蒲公英10~20份,荆芥10~20份,川楝子10~20份。
2.根据权利要求1所述防治龟头炎的中药洗液,其特征在于,所述中药洗液中各种原料药的重量份数为:马齿苋10~15份,茵陈10~15份,青黛10~15份,苍术10~15份,七叶一枝花10~15份,百部10~15份,黄柏10~15份,苦参10~15份,地肤子10~15份,白藓皮10~20份,千里光10~20份,土茯苓10~20份,马齿苋10~20份,蛇床子10~20份,败酱草10~20份,黄芩10~20份,蒲公英10~20份,荆芥10~20份,川楝子10~20份。
3.根据权利要求1所述防治龟头炎的中药洗液,其特征在于,所述中药洗液中各种原料药的重量份数为:马齿苋10~20份,茵陈10~20份,青黛10~20份,苍术10~20份,七叶一枝花10~20份,百部10~20份,黄柏10~20份,苦参10~20份,地肤子10~20份,白藓皮10~15份,千里光10~15份,土茯苓10~15份,马齿苋10~15份,蛇床子10~15份,败酱草10~15份,黄芩10~15份,蒲公英10~15份,荆芥10~15份,川楝子10~15份。
4.一种如权利要求1~3中任一项所述防治龟头炎的中药洗液的制备方法,其特征在于,所述中药洗液的制备步骤包括:
a.将所述原料药放入粉碎机粉碎后过筛;
b.将过筛后剩下的颗粒物放入乙醇中加热回流提取2次;
c.再取上述乙醇提取后的药渣,加水加热回流提取2次;
d.将上述两种提取液合并浓缩;加高锰酸钾溶液搅拌均匀,紫外线消毒后罐装。
5.根据权利要求4所述防治龟头炎的中药洗液的制备方法,其特征在于,所述步骤a中,将所述原料药放入粉碎机粉碎后过100目细筛,使能通过100目筛的细粉量在达到30%,收集通过100目筛的原料细粉备用。
6.根据权利要求4所述防治龟头炎的中药洗液制备方法,其特征在于,所述步骤b中,将过筛后剩下的粗颗粒物放入乙醇中加热回流提取2次,每次1~2小时,将2次提取液合并静置。
7.根据权利要求4所述防治龟头炎的中药洗液的制备方法,其特征在于,所述步骤c中,将上述乙醇提取过的药渣加水加热回流提取2次,每次1~2小时,将2次提取液合并静置。
8.根据权利要求4所述防治龟头炎的中药洗液的制备方法,其特征在于,所述步骤d中,将上述两种提取液合并,减压浓缩相对密度为80℃时1.37的 滤液,回收乙醇,将所得滤液调整比重到1.60,加入过筛的细粉后搅匀;倒入0.5%高锰酸钾溶液中,搅拌均匀,用紫外线消毒后罐装。
9.一种如权利要求1~3中任一项所述防治龟头炎的中药洗液的制备方法,其特征在于,所述中药洗液剂的制备步骤进一步包括:将所述原料药混合,切碎,浸泡;将将浸泡好的原料药加热回流提取2次,每次1~2小时,将2次提取液合并静置;再将上述水提取过的药渣加5~8倍量60~70%乙醇加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述两种提取液合并,减压浓缩相对密度为80℃时1.35的滤液,回收乙醇,将所得滤液调整比重到1.60,减压得浸膏,加入0.5%高锰酸钾溶液浴搅拌均匀,混合成粘稠的液体,紫外线杀菌消毒后使用。
10.一种如权利要求1~3中任一项所述防治龟头炎的中药洗液的制备方法,其特征在于,所述中药洗液剂的制备步骤再一步包括:将所述原料药混合,切碎,浸泡加水煎煮2次,合并煎液,去除沉渣,上清液加入乙醇并过滤,滤液回收乙醇至净,最后用纯化水调整药液体积至每毫升药液相当于1g原药材,药液为黄褐色至棕褐色液体,加入0.5%高锰酸钾溶液浴搅拌均匀,混合成粘稠的液体,紫外线杀菌消毒后使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310752658.3A CN103721142A (zh) | 2013-12-30 | 2013-12-30 | 一种防治龟头炎的中药洗液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310752658.3A CN103721142A (zh) | 2013-12-30 | 2013-12-30 | 一种防治龟头炎的中药洗液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103721142A true CN103721142A (zh) | 2014-04-16 |
Family
ID=50445603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310752658.3A Pending CN103721142A (zh) | 2013-12-30 | 2013-12-30 | 一种防治龟头炎的中药洗液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103721142A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105148062A (zh) * | 2015-08-31 | 2015-12-16 | 张玉玲 | 一种用于包皮龟头炎的护理药剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1193524A (zh) * | 1997-03-17 | 1998-09-23 | 崔庆惠 | 一种洁阴洗剂 |
CN101879301A (zh) * | 2010-06-23 | 2010-11-10 | 党彬 | 一种治疗慢性宫颈炎的中草药制剂 |
-
2013
- 2013-12-30 CN CN201310752658.3A patent/CN103721142A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1193524A (zh) * | 1997-03-17 | 1998-09-23 | 崔庆惠 | 一种洁阴洗剂 |
CN101879301A (zh) * | 2010-06-23 | 2010-11-10 | 党彬 | 一种治疗慢性宫颈炎的中草药制剂 |
Non-Patent Citations (2)
Title |
---|
赵延海等: "中药外洗治疗念珠菌性龟头炎的临床观察", 《辽宁中医杂志》 * |
马全庆: "龟炎洗剂治疗龟头炎86例", 《中国民间疗法》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105148062A (zh) * | 2015-08-31 | 2015-12-16 | 张玉玲 | 一种用于包皮龟头炎的护理药剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102145111B (zh) | 一种治疗霉菌性阴道炎的中药组合物及其制备方法 | |
CN103751663B (zh) | 一种治疗肛周湿疹的中药外用制剂及其制备方法 | |
CN102178814B (zh) | 一种治疗滴虫性阴道炎的中药组合物及其制备方法 | |
CN103800772A (zh) | 一种防治阴道炎症的妇科外用洗液及其制备方法 | |
CN101869626A (zh) | 中药复方制剂舒阴液及其制备与应用 | |
CN103721139A (zh) | 一种治疗龟头炎的中药组合物及其制备方法 | |
CN101167934A (zh) | 金松止痒洗液 | |
CN103536826B (zh) | 一种治疗阴道炎的中药组合物及其制备方法 | |
CN108853183A (zh) | 一种蕲艾抑菌乳膏及其制备方法 | |
CN105381352A (zh) | 一种治疗妇科炎症的外用中药洗液 | |
CN102847021B (zh) | 一种治疗溃疡性结肠炎的灌肠剂及其制备方法 | |
CN102018807A (zh) | 一种治疗妇科滴虫性阴道炎的药物组合物及其制备方法 | |
CN103041247B (zh) | 一种治疗阴道炎的中药栓剂及其制备方法 | |
CN101856475B (zh) | 一种治疗妇科炎症的中药组合物及其制备方法 | |
CN103721138B (zh) | 一种治疗酒糟鼻的中药外用制剂及其制备方法 | |
CN106806764A (zh) | 一种治疗包皮炎的中药制剂 | |
CN102727824B (zh) | 一种治疗阴部炎性疾病的中药 | |
CN105396006A (zh) | 一种防治龟头炎的男用外用洗液及其制备方法 | |
CN103721142A (zh) | 一种防治龟头炎的中药洗液及其制备方法 | |
CN102145072A (zh) | 一种治疗小儿湿疹及皮炎类皮肤病的中药组合物 | |
CN105381353A (zh) | 一种预防男性包皮龟头炎的外用制剂 | |
CN108324920B (zh) | 一种治疗便秘的中药组合物及制备方法 | |
CN102988847A (zh) | 一种治疗阴道炎的药物组合物 | |
CN103721141A (zh) | 一种治疗慢性阴囊湿疹的外用制剂及其制备方法 | |
CN103599437A (zh) | 一种治疗阴道炎的中药药液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140416 |
|
RJ01 | Rejection of invention patent application after publication |